COMIRNATY KP.2 3 micrograms/dose injectable dispersion concentrate

2. What you need to know before your child starts receiving Comirnaty KP.2

Comirnaty KP.2 should not be administered

• if your child is allergic to the active substance or to any of the other components of this medicine (listed in section 6).

Warnings and precautions

Talk to your child's doctor, pharmacist, or nurse before your child receives the vaccine if your child:

• has ever had a severe allergic reaction or breathing problems after receiving any other vaccine or after receiving this vaccine in the past;
• is nervous about the vaccination process or has fainted after an injection with a needle;
• has a severe illness or infection with high fever. However, your child can be vaccinated if they have a mild fever or an upper respiratory tract infection such as a cold;
• has a bleeding disorder, bruises easily, or is taking a medicine to prevent blood clots;
• has a weakened immune system due to a disease such as HIV or due to a medicine, such as corticosteroids, that affects the immune system.

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) after vaccination with Comirnaty (see section 4). These disorders can occur within a few days of vaccination and have mainly occurred within 14 days. They have been observed more frequently after the second dose of vaccination and more frequently in young males. The risk of myocarditis and pericarditis appears to be lower in children between 5 and 11 years of age than in those between 12 and 17 years of age. Most cases of myocarditis and pericarditis recover. Some cases required intensive care support, and fatal cases have been observed. After vaccination, you should be alert to the signs of myocarditis and pericarditis, such as difficulty breathing, palpitations, and chest pain, and seek immediate medical attention if they occur.

As with any vaccine, Comirnaty KP.2 may not completely protect all people who receive it, and it is not known how long your child will be protected.

The efficacy of Comirnaty KP.2 may be lower in immunocompromised individuals. If your child is immunocompromised, they may receive additional doses of Comirnaty KP.2. In these cases, your child should continue to maintain physical precautions to help prevent COVID-19. Additionally, your child's close contacts should be vaccinated as appropriate. Discuss individual recommendations with your child's doctor.

Children

Comirnaty KP.2 3 micrograms/dose concentrate for dispersion for injection is not recommended for use in children under 5 years of age and over 11 years of age.

Pediatric formulations are available for children between 5 and 11 years of age. For more information, see the package leaflet for other formulations.

The vaccine is not recommended for use in infants under 6 months of age.

Other medicines and Comirnaty KP.2

Tell your child's doctor or pharmacist if your child is using, has recently used, or might use any other medicine or has recently received any other vaccine.

Pregnancy and breastfeeding

Comirnaty KP.2 3 micrograms/dose concentrate for dispersion for injection is not indicated for use in individuals over 5 years of age.

For detailed information on use in individuals over 5 years of age, see the package leaflet for other formulations.

Driving and using machines

Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your child's ability to use machines or perform activities such as cycling. Wait until these effects have disappeared before resuming activities that require your child's full attention.

3. How Comirnaty KP.2 is administered

If your child is an infant between 6 months and less than 12 months of age, they will receive Comirnaty KP.2 with a yellow capafter dilution as an injection of 0.3 mlinto a muscle in the thigh. If your child is an infant or a child of 1 year of age or older, they will receive Comirnaty KP.2 with a yellow capafter dilution as an injection of 0.3 mlinto a muscle in the thigh or into a muscle in the arm.

If your child has not completed a primary vaccination schedule against COVID-19 or has not had COVID-19 before, they will receive a maximum of three injections (the total number of doses needed as a primary schedule). It is recommended to receive the second dose 3 weeks after the first dose, followed by a third dose at least 8 weeks after the second dose, to complete the primary schedule.

If your child has previously completed a primary vaccination schedule against COVID-19 or has had COVID-19, they will receive 1 injection. If your child has previously received a COVID-19 vaccine, they should not receive a dose of Comirnaty KP.2 until at least 3 months after the most recent dose.

If your child turns 5 years of age between their doses of the primary schedule, they should complete the primary schedule with the same dose level of 3 micrograms.

If your child is immunocompromised, they may receive additional doses of Comirnaty KP.2.

Interchangeability

Your child may receive any Comirnaty vaccine, previous or current, for the primary schedule. Your child should not receive more than the total number of doses needed as a primary schedule. Your child should only receive the primary schedule once.

If you have any other questions about the use of Comirnaty KP.2, ask your child's doctor, pharmacist, or nurse.

4. Possible side effects

Like all vaccines, Comirnaty KP.2 can cause side effects, although not everybody gets them.

Very common side effects:may affect more than 1 in 10 people

• irritability (between 6 months and <2 years)< li>

• injection site: pain/pain on palpation, swelling
• fatigue, headache
• sleepiness (between 6 months and <2 years)< li>
• muscle pain, joint pain
• chills, fever
• diarrhea

Common side effects:may affect up to 1 in 10 people

• nausea
• vomiting («very common» in pregnant women 18 years of age and older and in immunocompromised individuals between 2 and 18 years of age)
• redness at the injection site («very common» in children between 6 months and 11 years of age and in immunocompromised individuals 2 years of age and older)
• enlargement of lymph nodes (observed more frequently after a booster dose)

Uncommon side effects:may affect up to 1 in 100 people

• malaise, feeling of weakness or lack of energy/sleepiness
• arm pain
• insomnia
• itching at the injection site
• allergic reactions such as skin rash («common» in children between 6 months and <2 years of age) or itching< li>
• decreased appetite («very common» in children between 6 months and <2 years of age)< li>
• dizziness
• excessive sweating, night sweats

Rare side effects:may affect up to 1 in 1,000 people

• temporary paralysis of one side of the face
• allergic reactions such as hives or swelling of the face

Very rare side effects:may affect up to 1 in 10,000 people

• inflammation of the heart muscle (myocarditis) or inflammation of the outer lining of the heart (pericarditis) that can lead to difficulty breathing, palpitations, or chest pain

Frequency not known(cannot be estimated from the available data)

• severe allergic reaction
• extensive swelling in the limb where the vaccine was administered
• swelling of the face (may occur in patients who have received dermal filler injections)
• a skin reaction that causes red spots or patches on the skin, which may look like a target or a «bull's eye» with a dark red center surrounded by lighter red rings (erythema multiforme)
• abnormal sensation in the skin, such as tingling or numbness (paresthesia)
• decreased sensitivity, especially in the skin (hypoesthesia)
• heavy menstrual bleeding (most cases do not appear to be serious and are temporary)

Reporting of side effects

If your child experiences any side effects, talk to your child's doctor, pharmacist, or nurse, even if they are not listed in this leaflet.

You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Comirnaty KP.2

Keep this medicine out of the sight and reach of children.

The following information on storage, expiry, and handling is intended for healthcare professionals.

Do not use this medicine after the expiry date which is stated on the carton and on the label after EXP. The expiry date is the last day of the month shown.

Store in a freezer at –90 °C to –60 °C.

Store in the original package to protect from light.

The vaccine will be received frozen at –90 °C to –60 °C. The frozen vaccine can be stored at –90 °C to –60 °C or at 2 °C to 8 °C after receipt.

If stored frozen at –90 °C to –60 °C, the vaccine packs of 10 vials can be thawed at 2 °C to 8 °C for 2 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Thawed vials (previously frozen): Once removed from the freezer, the unopened vial can be stored and transported refrigerated at 2 °C to 8 °C for a maximum of 10 weeks; do not exceed the expiry date printed (EXP). The outer packaging should be marked with the new expiry date at 2 °C to 8 °C. Once thawed, the vaccine cannot be re-frozen.

Before use, unopened vials can be stored for a maximum of 12 hours at temperatures between 8 °C and 30 °C.

Thawed vials can be handled in ambient light conditions.

After dilution, store the vaccine at 2 °C to 30 °C and use within 12 hours, which includes a transport time of up to 6 hours. Discard unused vaccine.

Do not use this vaccine if you notice visible particles in the dilution or a color change.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Content and Additional Information

Comirnaty KP.2 Composition

• The active ingredient of the COVID-19 mRNA vaccine (with modified nucleosides) is called KP.2-encoding mRNA. After dilution, the vial with a yellow capcontains 3 doses of 0.3 mlwith 3 micrograms of KP.2-encoding mRNA each.

• The other components are:

• ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
• 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
• 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
• cholesterol
• tromethamine
• tromethamine hydrochloride
• sucrose
• water for injectable preparations

Product Appearance and Container Content

The vaccine is a dispersion (pH: 6.9-7.9) of white to off-white color, presented in a 3-dose multidose vial, transparent (Type I glass), 2 ml, with a rubber stopper and a yellow plastic flip-off capwith an aluminum seal.

Size of the monodose vial package: 10 vials.

Marketing Authorization Holder

BioNTech Manufacturing GmbH

An der Goldgrube 12

55131 Mainz

Germany

Phone: +49 6131 9084-0

Fax: +49 6131 9084-2121

[email protected]

Manufacturers

BioNTech Manufacturing GmbH

Kupferbergterrasse 17-19

55116 Mainz

Germany

Pfizer Manufacturing Belgium NV

Rijksweg 12

Puurs-Sint-Amands, 2870

Belgium

For further information on this medicinal product, please contact the local representative of the marketing authorization holder.

• België/Belgique/Belgien, Luxembourg/Luxemburg: Pfizer S.A./N.V.,

Tél/Tel: +32 (0)2 554 62 11

• Česká republika: Pfizer, spol. s r.o., Tel: +420 283 004 111
• Danmark: Pfizer ApS, Tlf: +45 44 201 100
• Deutschland: BioNTech Manufacturing GmbH, Tel: +49 6131 90840
• Eesti: Pfizer Luxembourg SARL Eesti filiaal, Tel: +372 666 7500
• Ελλάδα: Pfizer Ελλάς A.E., Τηλ.: +30 210 6785 800
• España: Pfizer, S.L., Tel: +34914909900
• France: Pfizer, Tél +33 1 58 07 34 40
• Hrvatska: Pfizer Croatia d.o.o., Tel: +385 1 3908 777
• Ireland: Pfizer Healthcare Ireland, Tel: 1800 633 363 (toll free), +44 (0)1304 616161
• Ísland: Icepharma hf, Simi: +354 540 8000
• Italia: Pfizer S.r.l., Tel: +39 06 33 18 21
• Κύπρος: Pfizer Ελλάς Α.Ε. (Cyprus Branch), Tηλ: +357 22 817690
• Latvija: Pfizer Luxembourg SARL filiale Latvija, Tel.: +371 670 35 775
• Lietuva: Pfizer Luxembourg SARL filialas Lietuvoje, Tel. +370 52 51 4000
• Magyarország: Pfizer Kft, Tel: +36 1 488 3700
• Malta: Vivian Corporation Ltd., Tel: +35621 344610
• Norge: Pfizer AS, Tlf: +47 67 526 100
• Nederland: Pfizer BV, Tel: +31 (0)10 406 43 01
• Österreich: Pfizer Corporation Austria Ges.m.b.H, Tel: +43 (0)1 521 15-0
• Polska: Pfizer Polska Sp. z o.o., Tel.: +48 22 335 61 00
• Portugal: Laboratórios Pfizer, Lda., Tel: +351 21 423 5500
• România: Pfizer Romania S.R.L, Tel: +40 (0) 21 207 28 00
• Slovenija: Pfizer Luxembourg SARL, Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana, Tel.: +386 (0) 1 52 11 400

Slovenská republika: Pfizer Luxembourg SARL, organizacná zložka, Tel: +421 2 3355 5500

• Suomi/Finland: Pfizer Oy, Puh/Tel: +358 (0)9 430 040
• Sverige: Pfizer AB, Tel: +46 (0)8 550 520 00
• United Kingdom (Northern Ireland): Pfizer Limited, Tel: +44 (0)1304 616161

Date of Last Revision of this Prospectus:

Scan the code with a mobile device to obtain the prospectus in different languages.

URL: www.comirnatyglobal.com

Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.

-----------------------------------------------------------------------------------------------------------------------------

This information is intended for healthcare professionals only:

If the child has not completed a primary vaccination schedule against COVID-19 or does not have a history of previous SARS-CoV-2 infection, administer Comirnaty KP.2 intramuscularly after dilution as a primary schedule of up to 3 doses (the total number of doses needed as a primary schedule); the second dose is administered 3 weeks after the first dose, followed by a third dose at least 8 weeks after the second dose to complete the primary schedule.

If the child has completed a primary vaccination schedule against COVID-19 or has a history of previous SARS-CoV-2 infection, administer Comirnaty KP.2 intramuscularly after dilution as a single dose of 0.3 ml. If the person has previously received a COVID-19 vaccine, they should receive a dose of Comirnaty KP.2 at least 3 months after the most recent dose.

Additional doses may be administered to individuals who are severely immunocompromised.

Traceability

In order to improve the traceability of biological medicinal products, the name and batch number of the administered product must be clearly recorded.

Handling Instructions Before Use

Comirnaty KP.2 must be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

• Checkthat the vial has a yellow plastic capand that the product nameis Comirnaty KP.2 3 micrograms/dose concentrate for injectable dispersion (infants and children from 6 months to 4 years of age).
• If the vial has a different product name on the label or a cap of a different color, consult the summary of product characteristics or the package leaflet of that formulation.
• If the vial is stored frozen, it must be thawed before use. Frozen vials should be transferred to a refrigerated area between 2 °C and 8 °C to thaw; a package of 10 vials may take 2 hours to thaw. Ensure that the vials are completely thawed before using them.
• When transferring the vials to storage between 2 °C and 8 °C, update the expiration date on the carton.
• Unopened vials can be stored for a maximum of 10 weeks between 2 °C and 8 °C;do not exceed the printed expiration date (EXP).
• Alternatively, individual frozen vials can be thawed for 30 minutes at temperatures up to 30 °C.
• Before use, unopened vials can be stored for a maximum of 12 hours at temperatures up to 30 °C. Thawed vials can be handled in ambient light conditions.

Dilution

• Allow the thawed vial to reach room temperature and gently invert it 10 times before dilution. Do not shake.
• Before dilution, the thawed dispersion may contain opaque, white to off-white amorphous particles.
• The thawed vaccine must be diluted in its original vial with 1.1 ml of a 9 mg/ml (0.9%) sodium chloride injectable solution, using a 21-gauge or finer needle and aseptic techniques.
• Equalize the vial pressure before withdrawing the needle from the vial stopper by drawing up 1.1 ml of air into the empty diluent syringe.
• Gently invert the diluted dispersion 10 times. Do not shake.
• The diluted vaccine should have the appearance of a white to off-white dispersion without visible particles. Do not use the diluted vaccine if it contains visible particles or a color change.
• The diluted vials must be labeled with the appropriate date and time of disposal.
• After dilution, the vials should be stored between 2 °C and 30 °C and used within 12 hours.
• Do not freeze or shake the diluted dispersion. If refrigerated, allow the diluted dispersion to reach room temperature before using it.

Preparation of 0.3 ml Doses

• After dilution, the vial contains 1.58 ml from which 3 dosesof 0.3 mlcan be extracted.
• Using aseptic technique, clean the vial stopper with a single-use antiseptic swab.
• Withdraw 0.3 mlof Comirnaty KP.2 for infants and children from 6 months to 4 years of age. Conventional syringes and needles can be used to withdraw 3 doses from the same vial.
• Each dose must contain 0.3 mlof vaccine.
• If the remaining vaccine volume in the vial cannot provide a full dose of 0.3 ml, discard the vial and the excess volume.
• Discard the vaccine that has not been used within 12 hours after dilution.

Disposal

Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.